Biosimilar developers should expect case-by-case evaluations, as the draft offers no hard rules on when CES will be waived. Developers are encouraged to consult the FDA early to understand evidentiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback